⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Hidradenitis Suppurativa Market Opportunity Forecast Report 2025: 7MM Market to Reach $7.8 Billion by 2034, Driven by New Biologics and Small-Molecule Launches Including Sonelokimab and Povorcitinib
globenewswire.com
ABBV
INCY
JNJ
MRK
NVS
SNY
Cure SMA Welcomes Broad FDA Approval of Itvisma™ for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support
prnewswire.com
NVS
Comprehensive Psoriasis Industry Assessment 2025-2035 - Asia-Pacific Real-World Evidence Reveals Strengthened and Effective Healthcare Strategies
globenewswire.com
ABBV
AMGN
NVS
JNJ
LLY
DNA Damaging Agents Market Grows at 11.67% CAGR, to Hit USD 46.31 Billion by 2034
globenewswire.com
XRAY
NVS
RUC
NIRA
TLZ
AZN
BMY
MRK
Liver Cancer Drug Market Poised to Reach US$ 17.2 Billion by 2033 Amid Rapid Advances in Targeted Therapies | Astute Analytica
globenewswire.com
BMY
MRK
AZN
ELVN
REGN
GILD
NVS
SNY
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
globenewswire.com
NVS
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
globenewswire.com
NVS
Companies Prioritize Revenue Performance with AI, ISG Says
businesswire.com
III
ANAB
XACT
ORCL
CRM
SAP
WDAY
ACN
IBM
MSFT
GOOG
AMZN
ADBE
NOW
INTU
PAYX
FIS
PAYC
SNOW
DDOG
MDB
PLTR
AI
SMCI
NVDA
AMD
INTC
QCOM
META
NFLX
CMCSA
VZ
T
CSCO
HPQ
DELL
PANW
CRWD
FTNT
ZBRA
CDNS
SNPS
MRVL
NXPI
MU
WDC
AMAT
LRCX
KLAC
ASML
ADI
TXN
ON
MPWR
AEHR
ARM
AVGO
AMGN
GILD
BMY
PFE
MRK
JNJ
LLY
ABBV
MDT
ISRG
BIIB
REGN
AZN
NVS
RHHBY
XOM
CVX
SHEL
TCEHY
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
YY
BEKE
NIO
LI
XPEV
RIVN
LCID
TSLA
GM
F
STLA
TM
HMC
VWAGY
BMW
DAI
GE
HON
BA
LMT
RTX
GD
NOC
CAT
DE
AGCO
CNH
J
CHTR
CMCSK
TMUS
ATVI
EA
TTWO
DIS
FOX
PARA
WBD
LYV
AMC
NCLH
CCL
RCL
DAL
UAL
AAL
LUV
JBLU
ALK
MAR
HLT
IHG
WYNN
LVS
MGM
CHKP
Zscaler
AKR
VAR
NICE
BOARD
FORM
PIG
INFSPM
PERF
FULL
CAP
EVER
JED
OPT
XOXO
ELEV
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
prnewswire.com
NVS
Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
prnewswire.com
NVS
BMY
JNJ
SRPT
GILD
TMO
DHR
SART
MRK
BDX